Spero Therapeutics, Inc. (SPRO): Price and Financial Metrics
GET POWR RATINGS... FREE!
SPRO POWR Grades
- SPRO scores best on the Value dimension, with a Value rank ahead of 50.54% of US stocks.
- SPRO's strongest trending metric is Momentum; it's been moving down over the last 31 weeks.
- SPRO's current lowest rank is in the Momentum metric (where it is better than 9.33% of US stocks).
SPRO Stock Summary
- SPRO's went public 3.62 years ago, making it older than only 11.61% of listed US stocks we're tracking.
- For SPRO, its debt to operating expenses ratio is greater than that reported by just 11.28% of US equities we're observing.
- With a price/sales ratio of 30.28, Spero Therapeutics Inc has a higher such ratio than 92.36% of stocks in our set.
- If you're looking for stocks that are quantitatively similar to Spero Therapeutics Inc, a group of peers worth examining would be AYLA, PULM, COCP, ARPO, and PLRX.
- SPRO's SEC filings can be seen here. And to visit Spero Therapeutics Inc's official web site, go to sperotherapeutics.com.
SPRO Stock Price Chart Interactive Chart >
SPRO Price/Volume Stats
|Current price||$15.32||52-week high||$23.64|
|Prev. close||$15.17||52-week low||$8.50|
|Day high||$15.50||Avg. volume||207,768|
|50-day MA||$13.96||Dividend yield||N/A|
|200-day MA||$15.20||Market Cap||454.47M|
Spero Therapeutics, Inc. (SPRO) Company Bio
Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections in the United States. It is developing SPR994, an oral carbapenem-class antibiotic for use in adults to treat MDR gram-negative infections; SPR741 that has completed Phase I clinical trial to treat MDR gram-negative infections in the hospital setting; SPR206, an agent that is in preclinical development stage to disrupt the outer membrane of gram-negative bacteria; and SPR720, an oral antibiotic that is in preclinical development stage for the treatment of pulmonary non-tuberculous mycobacterial infections. The company was founded in 2013 and is based in Cambridge, Massachusetts.
SPRO Latest News Stream
|Loading, please wait...|
SPRO Latest Social Stream
View Full SPRO Social Stream
Latest SPRO News From Around the Web
Below are the latest news stories about Spero Therapeutics Inc that investors may wish to consider to help them evaluate SPRO as an investment opportunity.
Spero Therapeutics Announces the Initiation of Bronchoalveolar Lavage and Renal Impairment Clinical Trials of SPR206
CAMBRIDGE, Mass., June 15, 2021 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing, and commercializing treatments in high unmet need areas involving multi-drug resistant bacterial infections and rare diseases, today announced the initiation of two Phase 1 trials of SPR206, an intravenously (IV)-administered next-generation polymyxin product candidate. SPR206 was derived from Spero’s potentiator p
Spero Therapeutics, Inc. ( NASDAQ:SPRO ) is possibly approaching a major achievement in its business, so we would like...
When you offer your home as a short-term rental through services like Airbnb, HomeAway, and VRBO, there are ways you can keep your income taxes to a minimum.
CAMBRIDGE, Mass., May 28, 2021 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multi-drug resistant bacterial infections and rare diseases, today announced that on May 28, 2021, the Compensation Committee of Spero’s Board of Directors granted non-qualified stock option awards to purchase an aggregate of 36,000 shares of its common stock to seven new employees under the Spero Therapeutics, Inc. 2019 Inducement Equity Incentive Plan, or the 2019 Inducement Plan. The stock options were granted as inducements material to the new employees becoming employees of Spero in accordance with Nasdaq Listing Rule 5635(c)(4). The 2019...
Spero Therapeutics Awarded up to $23 Million by the National Institute of Allergy and Infectious Diseases to Support the Development of SPR206
The National Institute of Allergy and Infectious Diseases will fund the continued clinical development of product candidate SPR206CAMBRIDGE, Mass., May 17, 2021 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing, and commercializing treatments in high unmet need areas involving multi-drug resistant bacterial infections and rare diseases, today announced that it has been awarded funding of $2.09 million, with the potential for up to an additional $21.3 million over 5 years, from the National Institute of Allergy and Infectious Diseases (NIAID), one of 27 institutes and centers that make up the National Institutes of Health (NIH). The funding will support the further clinical development of...
SPRO Price Returns
Continue Researching SPROWant to do more research on Spero Therapeutics Inc's stock and its price? Try the links below:
Spero Therapeutics Inc (SPRO) Stock Price | Nasdaq
Spero Therapeutics Inc (SPRO) Stock Quote, History and News - Yahoo Finance
Spero Therapeutics Inc (SPRO) Stock Price and Basic Information | MarketWatch